<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EPIRUBICIN HYDROCHLORIDE</span><br/>(e-pi-roo'bi-sin)<br/><span class="topboxtradename">Ellence<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antibiotic</span><br/><b>Prototype: </b>Doxorubicin HCl<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg/25 mL, 200 mg/100 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Cytotoxic antibiotic with wide spectrum of antitumor activity and strong immunosuppressive properties. Intercalates with preformed
         DNA residues, blocking effective DNA and RNA transcription.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Highly destructive to rapidly proliferating cells. Utilized effectively in the treatment of breast carcinomas. Indicated by
         tumor regression.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for axillary node-positive breast cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to epirubicin and other related drugs; marked myelosuppression, impaired cardiac function; previous treatment
         with maximum doses of epirubicin, doxorubicin, or daunorubicin; pregnancy (category D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Arrhythmias; liver dysfunction; severe renal insufficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100120 mg/m<sup>2</sup> infused over 35 min on day 1 of a 34 wk cycle or 5060 mg/m<sup>2</sup> on day 1 and 8 of a 34 wk cycle<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Pregnant women should <b>
<small>NOT</small>
</b> prepare or administer this drug. Wear protective goggles, gowns and disposable gloves and masks when handling this drug.
                     Discard <b>
<small>ALL</small>
</b> equipment used in preparation of this drug in high-risk, waste-disposal bags for incineration. Treat accidental contact with
                     skin or eyes by rinsing with copious amounts of water followed by prompt medical attention.
                     				
                  </li>
<li>
                     					Note: Reduce dosages when serum creatinine &gt;5 mg/dL or AST 24 times the upper limit of normal.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Epirubicin is manufactured as a preservative-free ready-to-use solution. The contents of a vial must be used within 25 h
                  of first penetrating the rubber stopper. Discard unused solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Measure ordered dose and inject into a port of a freely flowing IV solution of D5W or NS over 35 min. <b>
<small>DO NOT</small>
</b> give by direct IV push into a vein. Avoid IV sites that enter small veins or repeated injections into the same vein. Monitor
                  IV site closely for S&amp;S of extravasation and if suspected, notify physician immediately.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">alkaline solutions</span> (including <b>sodium bicarbonate</b>), <b>fluorouracil, ifosfamide, heparin, fluorouracil.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store between 2°8° C (36°46° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Lethargy,</span> fever. <span class="typehead">CV:</span> Asymptomatic decrease in LVEF, CHF. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, mucositis, diarrhea,</span> anorexia. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Leukopenia, neutropenia, anemia, thrombocytopenia, AML</span>. <span class="typehead">Skin:</span>
<span class="speceff-common">Alopecia, injection site reaction,</span> rash, itching, skin changes. <span class="typehead">Other:</span>
<span class="speceff-common">Amenorrhea, hot flashes, infection, conjunctivitis/keratitis</span>, <span class="speceff-life">secondary acute myelogenous leukemia</span> (related to cumulative dose).
      			 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cimetidine</b> increases epirubicin levels; concomitant use with cardioactive drugs (e.g., <span class="classification">calcium channel blockers</span>). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Widely distributed, 77% protein bound, concentrated in red blood cells. <span class="typehead">Metabolism:</span> Extensively metabolized in liver, blood and other organs. Clearance is reduced in patients with hepatic impairment. <span class="typehead">Elimination:</span> Primarily excreted in bile, some urinary excretion; clearance decreases in older adult female patients. <span class="typehead">Half-Life:</span> 33 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician of any of the following: neutrophil count 3, recent MI, suspicion of severe myocardial insufficiency.
         </li>
<li>Obtain baseline and periodic (before each cycle of therapy) cardiac evaluation: left ventricular ejection fraction, ECG and
            ECHO (tests are recommended especially in the presence of risk factors of cardiac toxicity).
         </li>
<li>Monitor cardiac status closely throughout therapy as the risk of developing severe CHF increases rapidly when cumulative doses
            approach 900 mg/m<sup>2</sup>. Report significant ECG changes immediately. Report immediately S&amp;S of the following: tachycardia, gallop rhythm, pleural
            effusion, pulmonary edema, dependent edema, ascites, or hepatomegaly.
         </li>
<li>Lab tests: Baseline and periodic (before each cycle of therapy) CBC with differential, platelet count, serum total bilirubin,
            AST, serum creatinine.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review all literature regarding the adverse effects of epirubicin therapy carefully.</li>
<li>Report any of the following to physician immediately: Pain at the site of IV infusion, chest pain, palpitations, shortness
            of breath or difficulty breathing, sudden weight gain, swelling of hands, feet or legs, or any unexplained bleeding.
         </li>
<li>Be aware that your urine may turn red for 12 d after receiving this drug. This change is expected and harmless.</li>
<li>Do not take OTC cimetidine or any other OTC drug without consulting physician.</li>
<li>Use effective means of contraception (both men and women) while on epirubicin therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>